RNA
Atrium Therapeutics, Inc.
Nasdaq: RNA · San Diego, CA · Healthcare
$14.19-0.41 (-2.81%)Closed
Market Cap$242.7M
Cash$72.3Mmost recent
Runway7 mo$31.1M Q burn
P/E (TTM)—EPS $-2.15
52-Wk Range$11.18 – $16.54
Avg Volume427.0K3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$14.19-3.8%
Pipeline
Drug candidates sponsored by Atrium Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 1 | ATR 1072 | Cardiac Glycogenosis+3 more | Not yet recruiting | 2028-05 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for RNA. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.